Suppr超能文献

保守性手术治疗对恶性卵巢生殖细胞肿瘤的影响。

The influence of conservative surgical practices for malignant ovarian germ cell tumors.

作者信息

Chan John K, Tewari Krishnansu S, Waller Sarah, Cheung Michael K, Shin Jacob Y, Osann Kathryn, Kapp Daniel S

机构信息

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco School of Medicine, UCSF Helen Diller Family, Comprehensive Cancer Center, San Francisco, California 94143-1702, USA.

出版信息

J Surg Oncol. 2008 Aug 1;98(2):111-6. doi: 10.1002/jso.21079.

Abstract

OBJECTIVE

To evaluate demographics, survival, and surgical trends for patients with malignant ovarian germ cell tumors.

METHODS

SEER data abstracted from 1988 to 2001 and analyzed using Kaplan-Meier and Cox regression models.

RESULTS

Of 760 patients, the median age was 23 years. Seventy-six percent of patients presented with stage I-II disease, and 24% with stage III-IV. Fifty-five percent were immature teratomas, 32% dysgerminomas, and 13% yolk sac tumors. Fertility-preserving surgery was performed in 41.2% (n = 313) of patients. In those <45 years old, the use of fertility-preserving surgery increased from 40.5% to 44.5% to 48.4% over the time periods 1988-1992, 1993-1997, 1998-2001 (P = 0.25). The survival of patients who underwent fertility-preserving surgery was not statistically different compared to those who underwent standard surgery (P = 0.26). Patients with stage I-II disease had improved survival compared to stage III-IV disease (97.6% vs. 85.5%, P < 0.001). The overall survival of women with dysgerminomas, immature teratomas, and yolk sac tumors was 99.5%, 94.3%, and 85.4%, respectively (P < 0.001). In multivariate analysis, older age, advanced stage, and yolk sac tumor histology predicted for poorer survival.

CONCLUSION

Our data suggests that the use of fertility-preserving surgery with concomitant surgical staging for germ cell cancers has increased without compromising survival.

摘要

目的

评估恶性卵巢生殖细胞肿瘤患者的人口统计学特征、生存率及手术趋势。

方法

提取1988年至2001年的监测、流行病学与最终结果(SEER)数据,并使用Kaplan-Meier和Cox回归模型进行分析。

结果

760例患者的中位年龄为23岁。76%的患者为Ⅰ-Ⅱ期疾病,24%为Ⅲ-Ⅳ期。55%为未成熟畸胎瘤,32%为无性细胞瘤,13%为卵黄囊瘤。41.2%(n = 313)的患者接受了保留生育功能手术。在年龄<45岁的患者中,1988 - 1992年、1993 - 1997年、1998 - 2001年期间保留生育功能手术的使用率从40.5%增至44.5%再增至48.4%(P = 0.25)。接受保留生育功能手术患者的生存率与接受标准手术患者相比无统计学差异(P = 0.26)。Ⅰ-Ⅱ期疾病患者的生存率高于Ⅲ-Ⅳ期疾病患者(97.6%对85.5%,P < 0.001)。无性细胞瘤、未成熟畸胎瘤和卵黄囊瘤女性患者的总生存率分别为99.5%、94.3%和85.4%(P < 0.001)。多因素分析显示,年龄较大、分期较晚和卵黄囊瘤组织学类型提示生存率较差。

结论

我们的数据表明,对于生殖细胞癌采用保留生育功能手术并同时进行手术分期的情况有所增加,且未影响生存率。

相似文献

1
The influence of conservative surgical practices for malignant ovarian germ cell tumors.
J Surg Oncol. 2008 Aug 1;98(2):111-6. doi: 10.1002/jso.21079.
4
Prognostic impact of laterality in malignant ovarian germ cell tumors.
Int J Gynecol Cancer. 2011 Feb;21(2):257-62. doi: 10.1097/IGC.0b013e31820581e5.
6
Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
Gynecol Oncol. 2017 Dec;147(3):493-496. doi: 10.1016/j.ygyno.2017.10.010. Epub 2017 Oct 9.
7
Laparoscopic management of early-stage malignant nonepithelial ovarian tumors: surgical and survival outcomes.
Int J Gynecol Cancer. 2013 Feb;23(2):249-55. doi: 10.1097/IGC.0b013e318272e754.
8
Trends in the surgical management of malignant ovarian germcell tumors.
Gynecol Oncol. 2020 Apr;157(1):89-93. doi: 10.1016/j.ygyno.2020.01.033. Epub 2020 Jan 31.
9
Outcome and risk factors for recurrence in malignant ovarian germ cell tumors: a MITO-9 retrospective study.
Int J Gynecol Cancer. 2011 Nov;21(8):1414-21. doi: 10.1097/IGC.0b013e3182236582.

引用本文的文献

1
An Indian Perspective on the Management of Adolescent Ovarian Cancer.
Indian J Surg Oncol. 2025 Apr;16(2):421-426. doi: 10.1007/s13193-024-02120-8. Epub 2024 Oct 28.
2
Oncologic and fertility outcome in patients with advanced stage ovarian immature teratomas.
Gynecol Oncol Rep. 2025 Mar 11;58:101715. doi: 10.1016/j.gore.2025.101715. eCollection 2025 Apr.
3
Yolk sac ovarian cancer with mesenteric metastases.
BMJ Case Rep. 2025 Feb 11;18(2):e261399. doi: 10.1136/bcr-2024-261399.
4
Yolk Sac Tumor of the Ovary in Mosaic 46XX Turner Syndrome.
Int J Womens Health. 2024 Apr 16;16:629-635. doi: 10.2147/IJWH.S462375. eCollection 2024.
5
Obstetric Results after Fertility-Sparing Management of Non-Epithelial Ovarian Cancer.
Cancers (Basel). 2023 Aug 18;15(16):4170. doi: 10.3390/cancers15164170.
7
Paediatric Ovarian Dysgerminoma: A Case Report.
JNMA J Nepal Med Assoc. 2022 Nov 2;60(255):985-988. doi: 10.31729/jnma.7894.
8
Impact of Optimal Therapy and Prognostic Factors in Malignant Germ Cell Tumors of Ovary: 20 Years' Institutional Experience.
Indian J Surg Oncol. 2022 Sep;13(3):633-640. doi: 10.1007/s13193-022-01537-3. Epub 2022 May 2.
9
Ovarian Germ Cell Tumors: Pictorial Essay.
Diagnostics (Basel). 2022 Aug 24;12(9):2050. doi: 10.3390/diagnostics12092050.
10
Incidence and Survival Rates for Female Malignant Germ Cell Tumors: An Institutional Review.
Cureus. 2022 Apr 26;14(4):e24497. doi: 10.7759/cureus.24497. eCollection 2022 Apr.

本文引用的文献

1
Association of lymphadenectomy and survival in stage I ovarian cancer patients.
Obstet Gynecol. 2007 Jan;109(1):12-9. doi: 10.1097/01.AOG.0000249610.95885.ef.
3
Incidence and survival rates for female malignant germ cell tumors.
Obstet Gynecol. 2006 May;107(5):1075-85. doi: 10.1097/01.AOG.0000216004.22588.ce.
4
Fertility-sparing surgery for malignancies in women.
J Natl Cancer Inst Monogr. 2005(34):43-7. doi: 10.1093/jncimonographs/lgi011.
8
Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study.
J Pediatr Surg. 2004 Mar;39(3):424-9; discussion 424-9. doi: 10.1016/j.jpedsurg.2003.11.027.
9
The relative survival rate: a statistical methodology.
Natl Cancer Inst Monogr. 1961 Sep;6:101-21.
10
Reproductive function after conservative surgery and chemotherapy for malignant germ cell tumors of the ovary.
Obstet Gynecol. 2003 Feb;101(2):251-7. doi: 10.1016/s0029-7844(02)02508-5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验